https://www.selleckchem.com/pr....oducts/pf-562271.htm
Immune checkpoint inhibitor (ICI) use in advanced hepatocellular carcinoma (HCC) is increasing. Real-world data on efficacy and safety, however, are lacking. We conducted a retrospective review of all patients with advanced HCC seen at our center who received at least one dose of an ICI between May 2015 and June 2018. Data cutoff was December 31, 2018. Responses were evaluated using Response Evaluation Criteria in Solid Tumors version 1.1 criteria. Of 114 patients, 88.6% were male. Median age was 66 years, 96.5% had an Eastern Coopera
Curtir
Comentario
Compartilhar
